PMID- 29423051 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 3 DP - 2018 Jan 9 TI - Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. PG - 3353-3364 LID - 10.18632/oncotarget.23261 [doi] AB - B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several entities with indolent clinical manifestations but heterogeneous survival. Cytogenetic aberrations are now the standard prognostic predictors in chronic lymphocytic leukemia (CLL) but have been less investigated in other subtypes of B-CLPD. In this study, we detected cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 875 B-CLPD patients, based on a panel probes locating at 13q14, 11q22, 17p13 and CEP12. We identified del17p acted as the independent adverse cytogenetic predictor for overall survival (OS) in CLL. Del13q, del11q and del17p were adverse factors for OS in Waldenstrom's macroglobulinemia in the univariate analysis but lost their role in the multivariate analysis. Trisomy 12 acted as an independent poor factor for both marginal zone lymphoma (MZL) and unclassified B-CLPD (BCLPD-U) subtype. Del17p did not impact survival in MZL and BCLPD-U patients. These contrasting results indicate different roles of the same cytogenetic aberrations in the pathogenesis of each B-CLPD subtype. As del17p contributed to the poorest survival in CLL and desired extraordinary treatment strategy, the imitation of CLL strategy to other B-CLPD with del17p should be carefully advocated based on this study. FAU - Yi, Shuhua AU - Yi S AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Li, Zengjun AU - Li Z AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Zou, Dehui AU - Zou D AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Xiong, Wenjie AU - Xiong W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Li, Heng AU - Li H AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Cui, Rui AU - Cui R AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. AD - Department of Hematology, Tianjin First Center Hospital, Tianjin, P.R.China. FAU - Li, Chengwen AU - Li C AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Yan, Yuting AU - Yan Y AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Liu, Wei AU - Liu W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Lv, Rui AU - Lv R AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Yu, Zhen AU - Yu Z AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Chen, Weiwei AU - Chen W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Xu, Yan AU - Xu Y AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - An, Gang AU - An G AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Wang, Huijun AU - Wang H AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Ru, Kun AU - Ru K AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Cheng, Tao AU - Cheng T AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Wang, Jianxiang AU - Wang J AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. FAU - Qiu, Lugui AU - Qiu L AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China. LA - eng PT - Journal Article DEP - 20171215 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5790468 OTO - NOTNLM OT - B-cell chronic lymphoproliferative disorders OT - chronic lymphocytic leukemia OT - cytogenetic aberration OT - del 17p OT - prognosis COIS- CONFLICTS OF INTEREST The authors declare that they have no competing interests. EDAT- 2018/02/10 06:00 MHDA- 2018/02/10 06:01 PMCR- 2018/01/09 CRDT- 2018/02/10 06:00 PHST- 2017/06/26 00:00 [received] PHST- 2017/11/17 00:00 [accepted] PHST- 2018/02/10 06:00 [entrez] PHST- 2018/02/10 06:00 [pubmed] PHST- 2018/02/10 06:01 [medline] PHST- 2018/01/09 00:00 [pmc-release] AID - 23261 [pii] AID - 10.18632/oncotarget.23261 [doi] PST - epublish SO - Oncotarget. 2017 Dec 15;9(3):3353-3364. doi: 10.18632/oncotarget.23261. eCollection 2018 Jan 9.